Solid Bioscience Stock Price, News & Analysis

Solid Biosciences (NASDAQ: SLDB), a life sciences company focused on developing precision genetic medicines for neuromuscular and cardiac diseases, announced its participation in the upcoming Jefferies Global Healthcare Conference. President and CEO Bo Cumbo and Chief Medical Officer Gabriel Brooks will engage in a fireside chat on June 4, 2025, at 2:00 pm ET. The presentation will be accessible via live webcast on the company's website's Investor Events page, with a replay available for 30 days afterward. Institutional investors can arrange meetings with management through their Jefferies representatives.

Solid Biosciences (NASDAQ: SLDB) reported Q1 2025 financial results and provided updates on its gene therapy pipeline. The company's cash position strengthened to $306.9 million, extending runway into H1 2027. Net loss widened to $39.3 million from $24.3 million year-over-year.

Key pipeline updates include: 1) Ongoing participant dosing in the Phase 1/2 INSPIRE DUCHENNE trial for SGT-003, with positive initial data showing robust microdystrophin expression and improved biomarkers; 2) FDA-cleared IND for SGT-212 for Friedreich's Ataxia, with first participant dosing expected in H2 2025; 3) Planned IND submission for SGT-501 for CPVT in H1 2025.

The company's proprietary capsid AAV-SLB101 has secured 19 partnership agreements, with more expected. R&D expenses increased to $30.9 million, primarily due to increased costs for SGT-003 development.

Solid Biosciences (Nasdaq: SLDB), a life sciences company focused on developing precision genetic medicines for neuromuscular and cardiac diseases, has announced its upcoming participation in The Citizens Life Sciences Conference.

The company's President and CEO, Bo Cumbo, will engage in a fireside chat scheduled for Wednesday, May 7, at 12:30 pm ET. Interested parties can access the presentation through a live webcast available on the Events page of the company's Investors section website.

Key Details:

• Event: The Citizens Life Sciences Conference
• Format: Fireside Chat
• Date & Time: May 7, 12:30 pm ET
• Replay Availability: 30-day archive access

Institutional investors seeking management meetings during the conference are advised to contact their Citizens representative.

Solid Biosciences will present data from their INSPIRE DUCHENNE Phase 1/2 trial for SGT-003, a next-generation gene therapy for Duchenne muscular dystrophy, at the upcoming ASGCT Annual Meeting in New Orleans.

The company will deliver three oral presentations and four poster presentations, highlighting:

• Initial safety and biomarker data from the INSPIRE DUCHENNE study
• Insights into AAV-SLB101, a novel muscle-tropic capsid
• Gene transfer potential in natural seropositivity cases
• Advanced quantification and characterization methods

CEO Bo Cumbo emphasized the company's progress in next-generation capsid design and their commitment to developing precision genetic medicines for rare neuromuscular and cardiac diseases. The presentations will take place between May 13-17, 2025, featuring research from leading scientists and medical professionals.

Solid Biosciences (SLDB), focused on developing precision genetic medicines for neuromuscular and cardiac diseases, has announced its participation in two upcoming investor conferences.

The company will present at the 24th Annual Needham Virtual Healthcare Conference on April 10, 2025, at 2:15 pm ET, featuring President and CEO Bo Cumbo and Chief Medical Officer Gabriel Brooks. A live webcast will be available on the company's website with a 90-day replay period.

Additionally, management will conduct one-on-one meetings at the Piper Sandler Spring Biopharma Symposium in Boston, MA on April 17, 2025. Institutional investors can arrange meetings through their Needham or Piper Sandler representatives.

Solid Biosciences (NASDAQ: SLDB) has announced the granting of 43,374 restricted stock units (RSUs) to three newly hired employees. The RSUs are structured with a four-year vesting schedule, with 25% vesting annually on each grant date anniversary. The equity awards, issued under the Company's 2024 Inducement Stock Incentive Plan, are contingent upon continued employment through each vesting date. This compensation package was designed as an inducement for employment and complies with Nasdaq Listing Rule 5635(c)(4).

Solid Biosciences (SLDB) has announced its upcoming presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in Dallas, TX, scheduled for March 16-19, 2025. The presentation will focus on data from the Phase 1/2 INSPIRE DUCHENNE trial, which evaluates SGT-003, their next-generation gene therapy candidate for Duchenne muscular dystrophy.

The oral presentation titled 'Initial Experience from the INSPIRE DUCHENNE Phase I/II Study of SGT-003 Microdystrophin Gene Therapy for Duchenne Muscular Dystrophy' will be delivered by Dr. Kevin Flanigan from Nationwide Children's Hospital on March 19, 2025, at 1:45 PM CT in the Coronado ABCD location.

Solid Biosciences (NASDAQ: SLDB) reported its Q4 and full-year 2024 financial results, highlighting positive initial data from the INSPIRE DUCHENNE trial for SGT-003, their next-generation Duchenne gene therapy. The company ended 2024 with $148.9 million in cash and secured an additional $200 million through a February 2025 offering, extending runway into H1 2027.

Key developments include:

• FDA IND clearance for SGT-212 treating Friedreich's ataxia, with first participant dosing expected in H2 2025
• INSPIRE DUCHENNE trial showed promising results with mean microdystrophin expression of 110% and 78% dystrophin positive fibers
• Planned FDA meeting in mid-2025 to discuss accelerated approval pathways for SGT-003

Financial results show R&D expenses increased to $96.4 million for 2024 (vs $76.6M in 2023), while net loss widened to $124.7 million (vs $96.0M in 2023). The company maintains partnerships with 19 institutions for its AAV-SLB101 capsid technology.